The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.
- Past awards
- 4
- 4 new
- Median first-year cost
- $675,368
- $2,679,618 in all
- Institutions
- 4
- 4 contact PIs
Awards by fiscal year
0
0
0
0
4
0
0
0
0
0
0
0
0
14151617181920212223242526
Fiscal years 2014 to 2026.
Most frequent institutions
- CEDARS-SINAI MEDICAL CENTER1
- DANA-FARBER CANCER INST1
- UNIV OF NORTH CAROLINA CHAPEL HILL1
- UNIVERSITY OF ROCHESTER1
Most frequent study sections
- Special Emphasis Panel (ZCA1 RPRB-L (A1))4
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| FY2018 | Advancing Analysis and Interpretation ofAdverse Events and PROs in Cancer Clinical Trials1U01CA232859-01 | Ganz, Patricia A.Rogatko, Andre | CEDARS-SINAI MEDICAL CENTER, CA | First-year cost $732,973 | Study section ZCA1 |
| FY2018 | Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)1U01CA233169-01 | Gray, Robert JWagner, Lynne I. | DANA-FARBER CANCER INST, MA | First-year cost $701,440 | Study section ZCA1 |
| FY2018 | Understanding Treatment Tolerability in Older Patients with Cancer1U01CA233167-01 | Mohile, Supriya G. | UNIVERSITY OF ROCHESTER, NY | First-year cost $649,295 | Study section ZCA1 |
| FY2018 | Analyzing and Interpreting PRO-CTCAE with CTCAE and Other Clinical Data to Characterize Drug Tolerability1U01CA233046-01 | Basch, Ethan M.Dueck, Amylou Constance | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | First-year cost $595,910 | Study section ZCA1 |
Newest fiscal year first, then first-year cost.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-12-0.3.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.